Single nanodrug shot may eliminate bad cholesterol permanently
Synopsis
A single CRISPR-based nanodrug injection — CTX310 — may permanently suppress bad cholesterol by silencing the ANGPTL3 gene, with parallel clinical trials running simultaneously in the US and China, potentially rendering daily statin pills obsolete.
Key Takeaways
CTX310 , a CRISPR gene-editing nanodrug, was tested on 15 volunteers in a trial led by the Cleveland Clinic across Australia , New Zealand , and Britain .
A parallel trial in China , linked to Shanghai Jiao Tong University , pursued the same ANGPTL3 -targeting approach.
The drug mimics a naturally occurring genetic mutation that keeps cholesterol and triglycerides permanently low and dramatically reduces heart disease risk.
LDL-C ('bad' cholesterol) is the leading driver of cardiovascular disease, which remains the number one cause of death worldwide .
ANGPTL3 and PCSK9 are now both validated gene targets in the next generation of lipid-lowering therapies.
Larger trials and long-term safety data are still required before regulatory submissions can be considered in any major market.
A single injection using CRISPR-based gene-editing nanotechnology could permanently suppress low-density lipoprotein cholesterol (LDL-C) — commonly known as 'bad' cholesterol — replacing the daily statin pills taken by millions worldwide, according to findings from two parallel clinical trials conducted in the United States and China.
What the trials found
Research led by the Cleveland Clinic, conducted across sites in Australia, New Zealand, and Britain, tested a gene-editing nanodrug called CTX310 on 15 volunteers. The therapy deploys tiny lipid nanoparticles to deliver a CRISPR gene-editing tool directly into liver cells, targeting a gene known as ANGPTL3, which regulates the concentration of fat in the bloodstream.
A separate trial in China, linked to researchers at Shanghai Jiao Tong University, pursued a parallel approach targeting the same biological pathway. Together, the two studies point toward a convergent scientific consensus: a one-time genetic intervention could replicate a naturally occurring mutation that keeps cholesterol and triglycerides at extremely low levels throughout a person's life.
The science behind CTX310
Some individuals are born with a natural mutation that inhibits ANGPTL3 function. These individuals exhibit exceptionally low cholesterol and triglyceride levels and rarely develop heart disease. CTX310 is designed to mimic that protective genetic switch in people who do not carry the mutation naturally.
LDL-C is a primary driver of cardiovascular disease — the leading cause of death worldwide. Elevated triglycerides compound that risk further. Current standard-of-care relies on daily statin medication, which requires lifelong adherence and is subject to patient non-compliance.
Why it matters
The prospect of a durable or permanent cholesterol-lowering solution addresses one of the most persistent challenges in preventive cardiology: medication adherence. A single-dose therapy targeting ANGPTL3 could be especially transformative for patients with familial hypercholesterolaemia, a hereditary condition that causes dangerously high LDL-C levels from birth and is resistant to conventional treatment.
The trials also place ANGPTL3 alongside PCSK9 as a validated therapeutic target in lipid management — a field that has already seen injectable antibody therapies gain regulatory approval but still requires repeated dosing every few weeks.
The competitive backdrop
The race to develop long-lasting lipid-lowering therapies has intensified significantly. PCSK9 inhibitors, currently available as biologic injections, reduce LDL-C substantially but must be administered every two to four weeks. RNA-based therapies targeting PCSK9 have extended dosing intervals to twice yearly. A gene-editing approach, if proven safe and durable, would represent a generational leap in treatment paradigm.
The parallel US and China trials signal that this is no longer a speculative frontier — it is an active, competitive clinical battleground with global implications for cardiovascular medicine.
What's next
Both trials remain in early phases, and larger, longer-duration studies will be required to establish the safety profile, durability of effect, and efficacy across diverse patient populations. Regulatory pathways for gene-editing therapies remain complex in all major markets. The coming months of follow-up data — particularly on how long the LDL-C suppression lasts — will be pivotal in determining whether CTX310 and its counterparts can advance toward broader clinical use.
Point of View
Including therapeutics that could eventually be worth hundreds of billions in annual market value. What mainstream coverage underplays is the regulatory asymmetry: gene-editing therapies face significantly different approval timelines and safety scrutiny in each jurisdiction, meaning Chinese patients could see access before Western counterparts — or vice versa — regardless of which trial produces stronger data. The targeting of ANGPTL3 also signals a strategic pivot away from the crowded PCSK9 inhibitor space, where incumbents like Repatha and Praluent already hold entrenched positions. If durability data holds up over multi-year follow-up, the statin industry — a market generating tens of billions annually — faces its most credible existential challenge yet.
NationPress
9 Sept 2026
Frequently Asked Questions
What is CTX310 and how does it work?
CTX310 is a gene-editing nanodrug that uses CRISPR technology delivered via tiny nanoparticles directly into liver cells to silence the ANGPTL3 gene, which controls fat levels in the blood. By mimicking a naturally protective genetic mutation, a single dose could permanently lower LDL-C and triglycerides without ongoing medication.
How many people were tested in the CTX310 trial?
The trial led by the Cleveland Clinic enrolled 15 volunteers and was conducted at sites in Australia , New Zealand , and Britain . A separate parallel trial was conducted in China with links to Shanghai Jiao Tong University .
Could this replace statins for cholesterol treatment?
Potentially, yes — but not yet. A single-dose gene-editing therapy could theoretically replace daily statins if long-term safety and durability are confirmed in larger trials. Current evidence is early-phase, and regulatory approval in any major market remains years away.
What is ANGPTL3 and why is it a drug target?
ANGPTL3 is a gene that regulates how much fat, including LDL cholesterol and triglycerides, circulates in the bloodstream. People born with a natural mutation that disables this gene have very low cholesterol and rarely develop heart disease, making it a compelling target for therapeutic gene editing.
How does CTX310 differ from existing cholesterol injections like PCSK9 inhibitors?
Unlike PCSK9 inhibitor injections, which must be administered every two to four weeks, CTX310 is designed as a one-time gene-editing intervention. RNA-based PCSK9 therapies have extended dosing to twice yearly, but a permanent gene-silencing approach — if validated — would represent a fundamentally different treatment paradigm.
